Vir Biotechnology, Inc. (NASDAQ:VIR)
| Market Cap | 1.94B+90.4% |
| Revenue (ttm) | 303.23M+1495.9% |
| Net Income | -251.68M+54.3% |
| EPS | -1.86+53.5% |
| Shares Out | 168.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,561,874 |
| Open | 11.32 |
| Previous Close | 11.60 |
| Day's Range | 11.32 - 11.77 |
| 52-Week Range | 4.82 - 11.94 |
| Beta | 1.59 |
| Analysts | Buy |
| Price Target | 23.50(+103.99%) |
| Earnings Date | Nov 4, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About VIR
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VIR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VIR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VIR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VIR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
VIR Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Segment revenue | $238.95M | 63.85% |
| Licenses, collaborations and contingent consideration, net | $41.21M | 11.01% |
| Personnel | $28.51M | 7.62% |
| Contract manufacturing | $23.97M | 6.40% |
| Clinical costs | $22.53M | 6.02% |
| Other R&D | $19.06M | 5.09% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New VIR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VIR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VIR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $53.02M |
| IWMiShares Russell 2000 ETF | $41.32M |
| VBVanguard Morningstar Small-Cap ETF | $38.19M |
| XBIState Street SPDR S&P Biotech ETF | $30.94M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $21.88M |
| VXFVanguard Extended Market ETF | $15.48M |
Estimated from each fund’s disclosed top holdings × AUM
VIR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VIR’s recent data — informational, not investment advice